Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Lymphoma

  Free Subscription

Articles published in Br J Dermatol

Retrieve available abstracts of 83 articles:
HTML format

Single Articles

    July 2021
  1. GAMBICHLER T, Boms S, Hessam S, Tischoff I, et al
    Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination.
    Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20630.
    PubMed     Abstract available

    June 2021
  2. SKAYEM C, Beylot-Barry M, de Masson A, Dereure O, et al
    Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases.
    Br J Dermatol. 2021 Jun 15. doi: 10.1111/bjd.20580.
    PubMed     Abstract available

    May 2021
  3. JONAK C, Alkon N, Rindler K, Rojahn TB, et al
    Single-cell RNAseq profiling in a patient with discordant primary cutaneous B and T cell lymphoma reveals micromilieu-driven immune skewing.
    Br J Dermatol. 2021 May 21. doi: 10.1111/bjd.20512.
    PubMed     Abstract available

  4. ZIMMERMANN C, Boisson M, Ram-Wolff C, Sadoux A, et al
    Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma.
    Br J Dermatol. 2021 May 3. doi: 10.1111/bjd.20432.
    PubMed     Abstract available

  5. MOLLOY K, Vico C, Ortiz-Romero PL, Scarisbrick JJ, et al
    Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sezary syndrome.
    Br J Dermatol. 2021;184:978-981.

    April 2021
  6. PORCU P, Nikbakht N
    New insights on treatment utilization and outcomes in early-stage mycosis fungoides.
    Br J Dermatol. 2021;184:594-595.

    March 2021
    Epidemiology of cutaneous lymphoma.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19829.

  8. HODAK E, Sherman S, Papadavid E, Bagot M, et al
    Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.
    Br J Dermatol. 2021;184:524-531.
    PubMed     Abstract available

    February 2021
  9. WINGE MCG, Iberri DJ, Novoa RA, Kwong BY, et al
    Telescope punch biopsy of normal-appearing skin to diagnose intravascular lymphoma.
    Br J Dermatol. 2021 Feb 1. doi: 10.1111/bjd.19711.

    January 2021
  10. WEHKAMP U, Mitteldorf C, Stendel S, Stranzenbach R, et al
    Most rare subtypes of cutaneous lymphoma display variable CD30 expression. Analysis of the German Cutaneous Lymphoma Network.
    Br J Dermatol. 2021 Jan 22. doi: 10.1111/bjd.19823.
    PubMed     Abstract available

    November 2020
  11. VERMEER MH, Nicolay JP, Scarisbrick JJ, Zinzani PL, et al
    The importance of assessing blood tumour burden in cutaneous T-cell lymphoma.
    Br J Dermatol. 2020 Nov 6. doi: 10.1111/bjd.19669.
    PubMed     Abstract available

    October 2020
  12. DOBOS G, de Masson A, Ram-Wolff C, Beylot-Barry M, et al
    Epidemiological changes in cutaneous lymphomas: an analysis of 8,593 patients from the French Cutaneous Lymphoma Registry.
    Br J Dermatol. 2020 Oct 31. doi: 10.1111/bjd.19644.
    PubMed     Abstract available

    September 2020
  13. GABES M
    Are existing quality-of-life instruments in cutaneous T-cell lymphoma of sufficient quality?
    Br J Dermatol. 2020 Sep 1. doi: 10.1111/bjd.19408.

    August 2020
  14. D'INCAN M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, et al
    Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas.
    Br J Dermatol. 2020 Aug 18. doi: 10.1111/bjd.19495.
    PubMed     Abstract available

  15. CHIRICO A, Henderson Berg MH, Roberge D, Pehr K, et al
    Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma.
    Br J Dermatol. 2020 Aug 15. doi: 10.1111/bjd.19490.
    PubMed     Abstract available

  16. TOUSSAINT F, Erdmann M, Grosch E, Schliep S, et al
    Transient response to nivolumab and relapse after infliximab in a patient with primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma.
    Br J Dermatol. 2020 Aug 7. doi: 10.1111/bjd.19470.
    PubMed     Abstract available

    July 2020
  17. MIRZA FN, Yumeen S, Girardi M
    Disparities in Outcomes of CD8(+) Cutaneous T Cell Lymphoma by Race and Presenting Lesion Location.
    Br J Dermatol. 2020 Jul 30. doi: 10.1111/bjd.19426.
    PubMed     Abstract available

    June 2020
  18. BHAT TS, Herbosa CM, Rosenberg AR, Sogade O, et al
    Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.
    Br J Dermatol. 2020 Jun 8. doi: 10.1111/bjd.19298.
    PubMed     Abstract available

  19. QUAGLINO P, Prince HM, Cowan R, Vermeer M, et al
    Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Study (PROCLIPI study).
    Br J Dermatol. 2020 Jun 1. doi: 10.1111/bjd.19252.
    PubMed     Abstract available

    May 2020
  20. DANGIEN A, Ram-Wolff C, Brice P, Battistella M, et al
    Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
    Br J Dermatol. 2020 May 14. doi: 10.1111/bjd.19220.
    PubMed     Abstract available

    February 2020
  21. HWANG S, Johnson A, Fabbro S, Hastings J, et al
    Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience.
    Br J Dermatol. 2020 Feb 20. doi: 10.1111/bjd.18961.
    PubMed     Abstract available

    December 2019
  22. TALPUR R
    Quality of life, Skindex-29, mycosis fungoides/Sezary syndrome.
    Br J Dermatol. 2019 Dec 11. doi: 10.1111/bjd.18710.

  23. SUN J, Wang Y
    KIR3DL2 in cutaneous T-cell lymphoma: from a promising biomarker to a potential therapeutic target.
    Br J Dermatol. 2019 Dec 5. doi: 10.1111/bjd.18682.

    September 2019
  24. RITCHIE S, Qureshi I, Molloy K, Yoo J, et al
    Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T cell lymphoma at a tertiary care centre: Should we avoid chemotherapy in conditioning regimes?
    Br J Dermatol. 2019 Sep 19. doi: 10.1111/bjd.18541.
    PubMed     Abstract available

  25. ENGELINA S, Saggu M, Yoo J, Shah F, et al
    Brentuximab a novel antibody therapy: Real-World Use Confirms Efficacy and Tolerability for CD30 positive cutaneous lymphoma.
    Br J Dermatol. 2019 Sep 16. doi: 10.1111/bjd.18535.
    PubMed     Abstract available

    Health-related quality of life in cutaneous T-cell lymphoma: examining all sides of the issue.
    Br J Dermatol. 2019 Sep 2. doi: 10.1111/bjd.18428.

    August 2019
  27. BYRNE N, Hughes R, Murphy LA, Kirby B, et al
    Remission of severe hidradenitis suppurativa following chemotherapy for Hodgkin's lymphoma.
    Br J Dermatol. 2019 Aug 9. doi: 10.1111/bjd.18423.
    PubMed     Abstract available

  28. ODUM N
    Deregulated signalling and inflammation in cutaneous T-cell lymphoma.
    Br J Dermatol. 2019 Aug 7. doi: 10.1111/bjd.18353.

    July 2019
  29. DOBOS G, Battistella M, Jouenne F, Mourah S, et al
    Challenges in the diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma.
    Br J Dermatol. 2019 Jul 6. doi: 10.1111/bjd.18328.
    PubMed     Abstract available

  30. HAO-ZE S, Liu YX, Jiang YQ, Chen SL, et al
    Clinical characteristics of primary cutaneous lymphoma: two centers analysis in China.
    Br J Dermatol. 2019 Jul 1. doi: 10.1111/bjd.18266.
    PubMed     Abstract available

    June 2019
  31. DUMONT M, Ram-Wolff C, Roelens M, Brice P, et al
    Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.
    Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18215.
    PubMed     Abstract available

  32. SUN J, Wang Y
    Brentuximab vedotin: unexpectedly good response in CD30(-) mycosis fungoides.
    Br J Dermatol. 2019;180:1300-1301.

    May 2019
  33. MOLLOY K, Jonak C, Sherida FJ, Woei-A-Jin H, et al
    Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Br J Dermatol. 2019 May 2. doi: 10.1111/bjd.18089.
    PubMed     Abstract available

    The emerging role of microRNAs in the molecular diagnosis of mycosis fungoides.
    Br J Dermatol. 2019;180:984-985.

  35. GELLER S, Lebowitz E, Pulitzer M, Myskowski PL, et al
    Understanding racial disparities in mycosis fungoides through international collaborative studies.
    Br J Dermatol. 2019;180:1263-1264.

  36. SCARISBRICK JJ, Quaglino P, Prince HM, Kim YH, et al
    Ethnicity in mycosis fungoides: white patients present at an older age and with more advanced disease.
    Br J Dermatol. 2019;180:1264-1265.

    April 2019
  37. GOYAL A, Goyal K, Bohjanen K, Pearson D, et al
    Epidemiology of primary cutaneous gamma/delta T-cell lymphoma and subcutaneous panniculitis-like T-cell lymphoma in the United States from 2006-2015: A Surveillance, Epidemiology, and End Results-18 analysis.
    Br J Dermatol. 2019 Apr 5. doi: 10.1111/bjd.17985.
    PubMed     Abstract available

    March 2019
  38. SEMENOV YR, Rosenberg AR, Herbosa C, Mehta-Shah N, et al
    Health-related quality of life and economic implications of cutaneous T-cell lymphoma.
    Br J Dermatol. 2019 Mar 28. doi: 10.1111/bjd.17941.
    PubMed     Abstract available

  39. DEQUIDT L, Franck N, Sanchez-Pena P, Dalle S, et al
    Cutaneous lymphomas appearing under biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database.
    Br J Dermatol. 2019 Mar 5. doi: 10.1111/bjd.17834.
    PubMed     Abstract available

  40. WANG Y, Bagot M
    Updates in cutaneous lymphoma: evidence-based guidelines for the management of cutaneous lymphoma 2018.
    Br J Dermatol. 2019;180:443-444.

    February 2019
  41. DANGIEN A, Beylot-Barry M, Battistella M, Ram-Wolff C, et al
    Clinical presentation, therapeutic approach and outcome of primary cutaneous marginal zone B-cell lymphoma presenting as AL amyloidoma of the skin.
    Br J Dermatol. 2019 Feb 22. doi: 10.1111/bjd.17821.
    PubMed     Abstract available

  42. BONNET P, Battistella M, Roelens M, Ram-Wolff C, et al
    Association of autoimmunity and long-term complete remission in patients with Sezary syndrome treated with mogamulizumab.
    Br J Dermatol. 2019;180:419-420.

    January 2019
  43. ENZAN N, Kitadate A, Tanaka A, Matsue K, et al
    Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: A clinicopathological study of 25 patients.
    Br J Dermatol. 2019 Jan 4. doi: 10.1111/bjd.17603.
    PubMed     Abstract available

    December 2018
  44. GILSON D, Whittaker SJ, Child FJ, Scarisbrick JJ, et al
    British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018.
    Br J Dermatol. 2018 Dec 17. doi: 10.1111/bjd.17240.

    October 2018
  45. BONNET P, Battistella M, Bouaziz JD, Ram-Wolff C, et al
    Thymic localization of erythrodermic cutaneous T-cell lymphoma.
    Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17340.
    PubMed     Abstract available

  46. DESCHAMPS O, Ram-Wolff C, Beylot-Barry M, Grange F, et al
    Treatment of mycosis fungoides and Sezary syndrome with romidepsin: a series of 32 cases of the French Study Group for Cutaneous Lymphoma.
    Br J Dermatol. 2018 Oct 9. doi: 10.1111/bjd.17269.
    PubMed     Abstract available

  47. MIURA H
    Image Gallery: 308-nm ultraviolet B excimer laser treatment for cutaneous B-cell lymphoma nodular lesions on the face.
    Br J Dermatol. 2018;179:e166.

    September 2018
  48. DEENEN NJ, Koens L, Jaspars EH, Vermeer MH, et al
    Pitfalls in diagnosing primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.
    Br J Dermatol. 2018 Sep 27. doi: 10.1111/bjd.17252.
    PubMed     Abstract available

  49. KEMPF W
    Multifocal anaplastic large cell lymphoma - insight into its biology and treatment.
    Br J Dermatol. 2018;179:565-566.

    August 2018
  50. FERTITTA L, Sicre de Fontbrune F, Battistella M, De Masson A, et al
    Folliculotropic Mycosis fungoides associated with GATA2 deficiency: a new skin manifestation.
    Br J Dermatol. 2018 Aug 12. doi: 10.1111/bjd.17081.
    PubMed     Abstract available

    July 2018
  51. CONNOLLY A, Grandi V, Stefanato CM, Palmer R, et al
    Primary cutaneous CD30(+) anaplastic large cell lymphoma associated with fingolimod.
    Br J Dermatol. 2018 Jul 14. doi: 10.1111/bjd.17003.
    PubMed     Abstract available

    May 2018
  52. CHRISTENSEN L, Cooper K, Honda K, Mansur D, et al
    Relapse rates in patients with unilesional primary cutaneous B cell lymphoma treated with radiation therapy: a single-institution experience.
    Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16783.
    PubMed     Abstract available

    March 2018
  53. MELCHERS RC, Willemze R, Bekkenk MW, de Haas ERM, et al
    Evaluation of treatment results in multifocal primary cutaneous anaplastic large cell lymphoma: Report of the Dutch Cutaneous Lymphoma Group.
    Br J Dermatol. 2018 Mar 1. doi: 10.1111/bjd.16501.
    PubMed     Abstract available

    February 2018
  54. ORLOWSKA D, Selman LE, Beynon T, Radcliffe E, et al
    "It's a traumatic illness, traumatic to witness." A qualitative study of the experiences of bereaved family caregivers of patients with cutaneous T-cell lymphoma.
    Br J Dermatol. 2018 Feb 16. doi: 10.1111/bjd.16447.
    PubMed     Abstract available

    January 2018
  55. KWATRA SG, Boozalis E, Kwatra MM
    Effects of neuroimmune axis modulation by aprepitant on anti-pruritic and global disease severity in patients with cutaneous T-cell lymphoma.
    Br J Dermatol. 2018 Jan 20. doi: 10.1111/bjd.16363.
    PubMed     Abstract available

  56. MARONAS-JIMENEZ L, Ortiz-Romero PL
    Aprepitant did not modify global disease activity in cutaneous T cell lymphomas.
    Br J Dermatol. 2018 Jan 20. doi: 10.1111/bjd.16374.
    PubMed     Abstract available

  57. HURABIELLE C, Leboeuf C, Ram-Wolff C, Meignin V, et al
    KIR3DL2 expression in patients with adult T-cell lymphoma/leukemia.
    Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16322.
    PubMed     Abstract available

    December 2017
  58. KAMSTRUP MR, Skov L, Zachariae C, Thyssen JP, et al
    Psoriasis and risk of malignant lymphoma: A population-based cohort study.
    Br J Dermatol. 2017 Dec 16. doi: 10.1111/bjd.16245.
    PubMed     Abstract available

  59. GONZALEZ-QUESADA A, Bastida J, Rivero-Vera JC, Piris-Pinilla MA, et al
    Image Gallery: Metachronic occurrence of primary cutaneous marginal zone B-cell lymphoma and primary cutaneous Rosai-Dorfman disease in the same patient.
    Br J Dermatol. 2017;177:e355.

    Brentuximab vedotin is an effective therapy for CD30(+) mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost?
    Br J Dermatol. 2017;177:1474-1475.

  61. LUO Y, Liu J
    Image Gallery: Primary cutaneous precursor B-lymphoblastic lymphoma in an infant.
    Br J Dermatol. 2017;177:e353.

    November 2017
  62. MARONAS-JIMENEZ L, Estrach T, Gallardo F, Perez A, et al
    Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.
    Br J Dermatol. 2017 Nov 18. doi: 10.1111/bjd.16128.
    PubMed     Abstract available

  63. CHEN L, Zhao X, Shi R, Zheng J, et al
    Image Gallery: Intravascular large B-cell lymphoma presenting with generalized telangiectasia.
    Br J Dermatol. 2017;177:e223.

    October 2017
  64. GELLER S, Myskowski PL, Kim YH, Moskowitz A, et al
    The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: Are we there yet?
    Br J Dermatol. 2017 Oct 10. doi: 10.1111/bjd.16052.
    PubMed     Abstract available

    September 2017
  65. STRANZENBACH R, Dippel E, Schlaak M, Stadler R, et al
    Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma: reply from authors.
    Br J Dermatol. 2017 Sep 10. doi: 10.1111/bjd.15972.
    PubMed     Abstract available

  66. LEWIS DJ, Kim YH, Duvic M
    Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.
    Br J Dermatol. 2017 Sep 10. doi: 10.1111/bjd.15970.
    PubMed     Abstract available

  67. LIAW TY, Liang CW
    Image Gallery: Generalized annular figurate erythema as an unusual presentation of angioimmunoblastic T-cell lymphoma.
    Br J Dermatol. 2017;177:e75.

  68. TENSEN CP, Vermeer MH
    MicroRNA-155 potentiates tumour development in mycosis fungoides.
    Br J Dermatol. 2017;177:618-620.

    August 2017
  69. DE BRITO M, Gazzani P, Amel-Kashipaz R, Vydianath B, et al
    Image Gallery: Secondary cutaneous involvement of the ear with systemic small lymphocytic lymphoma: a rare manifestation.
    Br J Dermatol. 2017;177:e26.

  70. DAWE RS
    Maintenance therapy with psoralen-ultraviolet A for mycosis fungoides: in the absence of evidence sitting on the fence is appropriate.
    Br J Dermatol. 2017;177:337-338.

    Psoralen-ultraviolet A maintenance in mycosis fungoides: the underlying question.
    Br J Dermatol. 2017;177:336-337.

    July 2017
  72. BAUER WM, Aichelburg MC, Griss J, Skrabs C, et al
    Molecular Classification of Tumor Cells in a Patient with Intravascular Large B-Cell Lymphoma.
    Br J Dermatol. 2017 Jul 22. doi: 10.1111/bjd.15841.
    PubMed     Abstract available

  73. STRANZENBACH R, Dippel E, Schlaak M, Stadler R, et al
    Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.
    Br J Dermatol. 2017 Jul 13. doi: 10.1111/bjd.15801.
    PubMed     Abstract available

  74. BAGOT M
    Folliculotropic mycosis fungoides is a heterogenous group.
    Br J Dermatol. 2017;177:17-18.

    June 2017
  75. LEE WJ, Kim YJ, Lee YJ, Won CH, et al
    VEGF protein expression is associated with a poor prognosis in cutaneous extranodal NK/T-cell lymphoma patients.
    Br J Dermatol. 2017 Jun 9. doi: 10.1111/bjd.15720.
    PubMed     Abstract available

  76. ADAMSKI H, Ingen-Housz-Oro S, Machet L, Carriou AC, et al
    Lymphomatoid papulosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma: 3 cases.
    Br J Dermatol. 2017 Jun 1. doi: 10.1111/bjd.15698.
    PubMed     Abstract available

    May 2017
    Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices.
    Br J Dermatol. 2017;176:1129-1130.

    April 2017
  78. KEMPF W
    Cutaneous lymphomas in childhood and adolescence: much needed new data.
    Br J Dermatol. 2017;176:857-858.

    August 2016
  79. GRIJSEN ML, Mtayangulwa RG, Naafs B, Jansen P, et al
    The clinical spectrum of mycosis fungoides in Tanzania, East-Africa.
    Br J Dermatol. 2016 Aug 16. doi: 10.1111/bjd.14963.
    PubMed     Abstract available

  80. KEMPF W
    TOX - what role does it play in cutaneous lymphomas?
    Br J Dermatol. 2016;175:248-9.

    Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.
    Br J Dermatol. 2016;175:246-7.

    July 2016
    Cutaneous T-cell lymphomas: an urgent need for more improved therapies.
    Br J Dermatol. 2016;175:14-5.

    May 2016
  83. LECAMWASAM K, Mathew B, Gilson D, Burton C, et al
    Correspondence article regarding CD68 as a marker of CD8+ lymphoid proliferation suggested by Wobser et al.
    Br J Dermatol. 2016;174:1158-9.

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.